By Diane Lietz, MSN, APRN, FNP-C | VGM Health | 5 min read
Last week, I shared my own breast health story and why I'll always nudge you toward your mammogram. This week, I want to answer the question I hear most often from women in my practice: "Will hormone therapy raise my breast cancer risk?"
Many women avoid even asking about hormone therapy because they're afraid of breast cancer. That fear makes sense. For more than 20 years, it's what women were told. And with my own family history, it's a question I've thought about personally, too. But the research has continued, and the picture is more nuanced than the headlines.
Where the fear started
In 2002, a large study called the Women's Health Initiative (WHI) reported that women taking a specific combination of hormones, conjugated equine estrogens plus a synthetic progestin called medroxyprogesterone acetate, had a higher rate of breast cancer. Millions of women stopped hormone therapy, and the FDA added a "black box" warning to hormone products.
What often got lost:
- The women in that study were, on average, in their early 60s, many years past menopause.
- The study tested one specific combination of hormones, not every type, dose, or delivery method.
What longer follow-up showed
The WHI also studied women who had a hysterectomy and took estrogen alone. In long-term follow-up published in JAMA in 2020, estrogen alone was associated with lower breast cancer incidence and fewer breast cancer deaths compared to placebo. The estrogen-plus-synthetic-progestin group, on the other hand, continued to show higher breast cancer incidence.
Does the type of progesterone matter?
It may. A large French study that followed about 80,000 women (the E3N cohort) found that hormone therapy containing micronized progesterone (which is identical to the progesterone your body makes) was not associated with the increased breast cancer risk seen with other, synthetic progestins.
An honest caveat: the evidence for longer-term use of micronized progesterone is less clear, and it is not proven to be risk-free. This is one of the reasons hormone therapy should always be individualized and monitored over time.
The FDA updated its warning
In November 2025, the FDA announced it would remove the statements about breast cancer, heart disease, and dementia from the black box warning on menopausal hormone therapy, and in February 2026 it approved the first updated labels. The FDA also recommended that labeling suggest starting hormone therapy before age 60 or within 10 years of menopause.
Not every expert agrees with every part of the change, and some warnings remain, for example the warning about endometrial (uterine) cancer for estrogen-only products in women who still have a uterus. But the starting point for the conversation is no longer a one-size-fits-all warning label. It's you: your symptoms, your history, and your goals.
If you've had breast cancer
For breast cancer survivors, decisions about hormones are more complex and need to be coordinated with your oncologist. A history of breast cancer deserves a careful, individualized conversation, not a blanket yes or no.
Recommendations change, and that's a good thing
Medicine isn't static. Screening guidelines have shifted over the years, and so has our understanding of hormone therapy. That's how good science works: as better research comes in, recommendations improve.
It's also why I keep up with the evidence, and why I believe your care should be built around you, not around a headline from twenty years ago.
The bottom line
- Hormone therapy isn't risk-free, and it isn't one-size-fits-all. The type of hormone, the dose, how it's taken, your age, and how long it's been since menopause all matter.
- "Hormones cause breast cancer" is too simple an answer. The higher risk in the WHI was seen with one specific combination, not with estrogen alone.
- Keep up with your screening. Whether or not you use hormones, your yearly mammogram still matters. Schedule it with your primary care provider or OB-GYN.
- Your history belongs in the conversation, including your family history and any past breast findings.
If fear of breast cancer has kept you from asking about hormone therapy, and you're navigating perimenopause or menopause, I'm always glad to walk through your symptoms, your history, and the evidence with you, one on one.
Questions about perimenopause, menopause, or hormone therapy? Start Your Free Quick Consult →
Diane Lietz, MSN, APRN, FNP-C
VGM Health
This article is for educational purposes only and isn't a substitute for personalized medical advice. Please talk with your own healthcare provider about whether hormone therapy is right for you.
References
- Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333. https://doi.org/10.1001/jama.288.3.321
- Chlebowski RT, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. 2020;324(4):369–380. https://doi.org/10.1001/jama.2020.9482
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111. https://doi.org/10.1007/s10549-007-9523-x
- U.S. Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. February 12, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
Diane Lietz, MSN, APRN, FNP-C is the founder and sole clinician at VGM Health in Springfield, IL. She offers in-person and telehealth care throughout Illinois.